Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Ovarian fibroma

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44346   clinical trials with a EudraCT protocol, of which   7374   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    4 result(s) found for: Ovarian fibroma. Displaying page 1 of 1.
    EudraCT Number: 2009-010095-23 Sponsor Protocol Number: AA-GYN-002 Start Date*: 2009-07-06
    Sponsor Name:Omrix Biopharmaceuticals Ltd
    Full Title: A prospective, controlled, randomized, multi-center, pivotal study evaluating the safety and efficacy of ADHEXIL in prevention and/or reduction of adhesions in gynecology surgery
    Medical condition: Adhesions in gynecology surgery. Surgeries involved will be ovarian cystectomy, endometriosis, inflammation, adhesiolysis Ovarian adhesion MedDRA 10067156 Tubal rupture MedDRA 10067553
    Disease: Version SOC Term Classification Code Term Level
    9.1 10014778 Endometriosis LLT
    9.1 10004433 Benign ovarian tumour LLT
    9.1 10053865 Benign fallopian tube neoplasm LLT
    9.1 10050697 Fallopian tube cyst LLT
    9.1 10061855 Fallopian tube neoplasm LLT
    9.1 10048991 Ovarian adenoma LLT
    9.1 10033132 Ovarian cyst LLT
    9.1 10033136 Ovarian cyst ruptured LLT
    9.1 10064257 Ovarian fibroma LLT
    9.1 10033236 Ovarian germ cell teratoma benign LLT
    9.1 10061535 Ovarian neoplasm LLT
    9.1 10052456 Parovarian cyst LLT
    9.1 10036049 Polycystic ovaries LLT
    9.1 10033139 Ovarian disorder LLT
    9.1 10033263 Ovarian haematoma LLT
    9.1 10065741 Ovarian haemorrhage LLT
    9.1 10058823 Ovarian mass LLT
    9.1 10033277 Ovarian prolapse LLT
    9.1 10033279 Ovarian rupture LLT
    9.1 10046988 Varicocele ovarian LLT
    9.1 10052094 Fallopian tube disorder LLT
    9.1 10065789 Fallopian tube obstruction LLT
    9.1 10065790 Fallopian tube perforation LLT
    9.1 10065791 Fallopian tube stenosis LLT
    9.1 10050468 Haematosalpinx LLT
    9.1 10061071 Congenital ovarian anomaly LLT
    9.1 10061062 Congenital fallopian tube anomaly LLT
    11.1 10067156 PT
    9.1 10060781 Haemorrhagic ovarian cyst LLT
    11.1 10067553 PT
    9.1 10033157 Ovarian enlargement LLT
    Population Age: Adults Gender: Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-004246-11 Sponsor Protocol Number: EDO-S101-1002 Start Date*: 2021-09-30
    Sponsor Name:Mundipharma Research Limited
    Full Title: A Phase 1/2 Study to Investigate the Safety, Pharmacokinetics and Efficacy of Tinostamustine, a First-in-Class Alkylating Histone Deacetylase Inhibition (HDACi) Fusion Molecule, in Patients with Ad...
    Medical condition: • Cohort 1: Relapsed/refractory Small Cell Lung Cancer • Cohort 2: Relapsed/refractory Soft Tissue Sarcoma • Cohort 3: Relapsed/refractory Triple-Negative Breast Cancer • Cohort 4: Relapsed/refr...
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10041071 Small cell lung cancer stage unspecified LLT
    23.0 100000004864 10084066 Triple negative breast cancer metastatic LLT
    20.0 100000004864 10033130 Ovarian cancer NOS LLT
    21.0 100000004864 10014735 Endometrial cancer NOS LLT
    20.0 100000004864 10002479 Angiosarcoma NOS LLT
    21.1 100000004864 10057043 Dermatofibrosarcoma LLT
    21.1 100000004864 10015103 Epithelioid sarcoma NOS LLT
    20.0 100000004864 10024193 Leiomyosarcoma NOS LLT
    20.0 100000004864 10024631 Liposarcoma NOS LLT
    22.1 100000004864 10082807 Solitary fibrous tumor LLT
    20.0 100000004864 10042866 Synovial sarcoma NOS LLT
    21.1 100000004864 10025556 Malignant fibrous histiocytoma NOS LLT
    20.0 100000004864 10029276 Neurofibrosarcoma NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-006147-25 Sponsor Protocol Number: UTEROXINE Start Date*: 2022-11-15
    Sponsor Name:Centre de Recherche en Santé de la Femme
    Full Title: Botulinum toxin type A injection in patients with chronic pelvic pain of uterine origin (severe dysmenorrhea and/or deep dyspareunia). Phase III, single-center, randomized study vs. control group
    Medical condition: PATIENTS WITH CHRONIC PELVIC PERINEAL PAIN OF UTERINE ORIGIN WITH VAS>4
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038604 - Reproductive system and breast disorders 10048581 Pelvic pain female LLT
    21.1 10038604 - Reproductive system and breast disorders 10064189 Chronic pelvic pain syndrome LLT
    21.1 10037175 - Psychiatric disorders 10078087 Genito-pelvic pain/penetration disorder PT
    21.1 10038604 - Reproductive system and breast disorders 10011990 Deep dyspareunia LLT
    20.1 10038604 - Reproductive system and breast disorders 10013934 Dysmenorrhea LLT
    Population Age: Adults Gender: Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-004274-15 Sponsor Protocol Number: Pelle-926-201 Start Date*: 2016-02-22
    Sponsor Name:PellePharm, Inc.
    Full Title: Double-Blind, Randomized, Vehicle-Controlled Proof of Concept Clinical Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas in Gorlin Syndr...
    Medical condition: Basal Cell Nevus Syndrome
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004850 10004151 Basal cell nevus syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jun 27 12:46:55 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA